[1] This paper evaluates the use of field data on the spatial variability of snow water equivalent (SWE) to guide the design of distributed snow models. An extensive reanalysis of results from previous field studies in different snow environments around the world is presented, followed by an analysis of field data on spatial variability of snow collected in the headwaters of the Jollie River basin, a rugged mountain catchment in the Southern Alps of New Zealand. In addition, area-averaged simulations of SWE based on different types of spatial discretization are evaluated. Spatial variability of SWE is shaped by a range of different processes that occur across a hierarchy of spatial scales. Spatial variability at the watershed-scale is shaped by variability in near-surface meteorological fields (e.g., elevation gradients in temperature) and, provided suitable meteorological data is available, can be explicitly resolved by spatial interpolation/extrapolation. On the other hand, spatial variability of SWE at the hillslope-scale is governed by processes such as drifting, sloughing of snow off steep slopes, trapping of snow by shrubs, and the nonuniform unloading of snow by the forest canopy, which are more difficult to resolve explicitly. Subgrid probability distributions are often capable of representing the aggregate-impact of unresolved processes at the hillslope-scale, though they may not adequately capture the effects of elevation gradients. While the best modeling strategy is case-specific, the analysis in this paper provides guidance on both the suitability of several common snow modeling approaches and on the choice of parameter values in subgrid probability distributions.
Background Psilocybin therapy has shown promise as a rapid-acting treatment for depression, anxiety, and demoralization in patients with serious medical illness (e.g., cancer) when paired with individual psychotherapy. This study assessed the safety and feasibility of psilocybin-assisted group therapy for demoralization in older long-term AIDS survivor (OLTAS) men, a population with a high degree of demoralization and traumatic loss. Methods Self-identified gay men OLTAS with moderate-to-severe demoralization (Demoralization Scale-II ≥8) were recruited from the community of a major US city for a single-site open-label study of psilocybin-assisted group therapy comprising 8–10 group therapy visits and one psilocybin administration visit (0·3–0·36 mg/kg po). Primary outcomes were rate and severity of adverse events, and participant recruitment and retention. The primary clinical outcome was change in mean demoralization from baseline to end-of-treatment and to 3-month follow-up assessed with a two-way repeated measures ANOVA. Trial registration: Clinicaltrials.gov (NCT02950467) Findings From 17 July 2017 to 16 January 2019, 18 participants (mean age 59·2 years (SD 4·4)) were enrolled, administered group therapy and psilocybin, and included in intent-to-treat analyses. We detected zero serious adverse reactions and two unexpected adverse reactions to psilocybin; seven participants experienced self-limited, severe expected adverse reactions. We detected a clinically meaningful change in demoralization from baseline to 3-month follow-up (mean difference -5·78 [SD 6·01], η p 2 = 0·47, 90% CI 0·21–0·60). Interpretation We demonstrated the feasibility, relative safety, and potential efficacy of psilocybin-assisted group therapy for demoralization in OLTAS. Groups may be an effective and efficient means of delivering psychotherapy pre- and post-psilocybin to patients with complex medical and psychiatric needs. Funding Carey Turnbull, Heffter Research Institute, NIMH R25 MH060482, NIH UL1 TR001872, River Styx Foundation, Saisei Foundation, Sarlo Foundation, Stupski Foundation, Usona Institute, US Department of Veterans Affairs (Advanced Neurosciences Fellowship and IK2CX001495).
Chronic administration of antidepressant drugs produce changes in neuroplasticity and behavior in rodents, effects that may be associated with the slow emergence of clinical therapeutic effects. Because of uncertainty over the effects of chronic antidepressant treatments in mice, these experiments compared the regulation of neurogenesis, mobilization of neurotrophins, and behavior produced by chronic antidepressant treatments between two inbred mouse strains, MRL/MpJ and C57BL/6J. The MRL/MpJ strain is associated with enhanced wound healing and tissue regeneration, whereas C57BL/6J mice are commonly used for behavioral studies. Proliferation and survival of hippocampal progenitor cells were measured using flow cytometry, a new platform that rapidly quantifies BrdU incorporation. Hippocampal cell proliferation was significantly increased following chronic administration of fluoxetine (5, 10 mg/kg; i.p. b.i.d.) or desipramine (5, 10 mg/kg; i.p. b.i.d.) for 21 days in MRL/MpJ mice, but not in C57BL/6J mice. Hippocampal progenitor cells born prior to chronic antidepressant treatments were not affected in either mouse strain. Protein levels of brain-derived neurotrophic factor (BDNF) in MRL/MpJ mice were elevated significantly in the frontal cortex, hippocampus, and amygdala following chronic fluoxetine treatment, but increased only in the frontal cortex by chronic desipramine. In contrast, BDNF levels in C57BL/6J mice were decreased in all regions except for the amygdala after chronic fluoxetine, and were decreased in the brain stem after chronic desipramine. Novelty-induced hypophagia was used to examine a behavioral effect produced by chronic antidepressant treatment. MRL/MpJ mice chronically administered fluoxetine or desipramine had significantly shorter latencies to consume food when exposed to a novel environment than untreated mice, whereas there were no effects on the behavior of C57BL/6J mice. In conclusion, robust effects of chronic antidepressant treatments on hippocampal cell proliferation and BDNF levels paralleled the ability of these drugs to produce changes in NIH behavior in MRL/MpJ, but none of these effects were produced in C57BL/6J mice. The greater responsiveness of MRL/MpJ mice may be important for drug discovery, for genetic studies and for understanding the neural mechanisms underlying the physiological and behavioral effects of chronic antidepressant treatments.
This study investigates causes behind correlations between snow and terrain properties in a 27 km 2 mountain watershed. Whereas terrain correlations reveal where snow resides, the physical processes responsible for correlations can be ambiguous. We conducted biweekly snow surveys at small transect scales to provide insight into late-season correlations at the basin scale. The evolving parameters of transect variograms reveal the interplay between differential accumulation and differential ablation that is responsible for correlations between snow and terrain properties including elevation, aspect, and canopy density. Elevation-induced differential accumulation imposes a persistent source of varariabity at the basin scale, but is not sufficient to explain the elevational distribution of snow water equivalent (SWE) on the ground. Differential ablation, with earlier and more frequent ablation at lower elevations, steepens the SWEelevation gradient through the season. Correlations with aspect are primarily controlled by differences in solar loading. Aspect related redistribution of precipitation by wind, however, is important early in the season. Forested sites hold more snow than nonforested sites at the basin scale due to differences in ablation processes, while open areas within forested sites hold more snow than covered areas due to interception. However, as the season progresses energetic differences between open and covered areas within forested sites cause differences induced by interception to diminish. Results of this study can help determine which accumulation and ablation processes must be represented explicitly and which can be parameterized in models of snow dynamics.
Contemporary research with classic psychedelic drugs (e.g. lysergic acid diethylamide (LSD) and psilocybin) is indebted to the 20th century researchers and clinicians who generated valuable clinical knowledge of these substances through experimentation. Several recent reviews that highlight the contributions of this early literature have focused on psychedelic-assisted individual psychotherapy modalities. None have attempted to systematically identify and compile experimental studies of psychedelic-assisted group therapy. In therapeutic settings, psychedelics were often used to enhance group therapy for a variety of populations and clinical indications. We report on the results of a systematic review of the published literature in English and Spanish on psychedelic-assisted group therapies. Publications are characterized by their clinical approach, experimental method, and clinical outcomes. Given the renewed interest in the clinical use of psychedelic medicines, this review aims to stimulate hypotheses to be tested in future research on psychedelic-assisted psychotherapy, group process, and interpersonal functioning.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.